Aprea Therapeutics Inc (APRE) Stock Price, Quote & News

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid...

Industry: Biotechnology

Sector: Healthcare

Phone: (215) 948-4119

Website: aprea.com

Address:

3805 Old Easton Road, Doylestown, United States

Bulltrader988 Oct. 25 at 8:17 PM

$APRE 👃👀 https://finviz.com/quote.ashx?t=APRE&ty=c&ta=1&p=d

0 · Reply

NewsAndFilings Oct. 25 at 2:28 PM

Weekly Rundown: $APRE Clinical Update $SNYR FOCUSfactor® Expansion $TOON $7.3 Million Financing $SIGL Major Encryption Milestone $SPTY Appoints Robert Fedder as CEO

0 · Reply

Bulltrader988 Oct. 24 at 2:36 PM

$APRE 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-provides-clinical-update-from-acesot-1051-trial-zv04tgf74l20.html

0 · Reply

MsGrumpy Oct. 24 at 2:02 PM

$APRE Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html

0 · Reply

NewsAndFilings Oct. 24 at 1:49 PM

0 · Reply

Giants67 Oct. 24 at 1:17 PM

$APRE Aprea Therapeutics, provided an update on the ongoing Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) study. https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html

0 · Reply

Tigerfromasia Oct. 23 at 10:11 PM

$APRE data is weak as fuck with 0 orr tbh but who gives a shit if we could get a pump

0 · Reply

Bulltrader988 Oct. 23 at 6:53 PM

$APRE tomorrow 👃👀

1 · Reply

Wakaas93 Oct. 23 at 3:52 PM

$APRE Results tomorrow Target $3 https://x.com/pportfolioooo/status/1980337875326828605?s=46

0 · Reply

Bulltrader988 Oct. 22 at 7:43 PM

$APRE "...A poster titled Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage will be presented at the forthcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on Friday, October 24, 2025..." 👃👀 https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-establishes-recommended-phase-2-dose-rp2d

0 · Reply

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Oct 15, 2025, 8:00 AM EDT - 10 days ago

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Oct 14, 2025, 8:00 AM EDT - 11 days ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 2 months ago

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Jun 25, 2025, 9:00 AM EDT - 4 months ago

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

May 14, 2025, 8:00 AM EDT - 5 months ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Mar 31, 2025, 8:30 AM EDT - 7 months ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 25, 2025, 8:30 AM EDT - 7 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 11, 2025, 8:30 AM EDT - 8 months ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Feb 5, 2025, 8:00 AM EST - 9 months ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Dec 11, 2024, 8:30 AM EST - 11 months ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Sep 9, 2024, 5:15 PM EDT - 1 year ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

May 28, 2024, 8:45 AM EDT - 1 year ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:01 PM EDT - 1 year ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 2, 2024, 9:15 AM EDT - 1 year ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Apr 10, 2024, 12:00 PM EDT - 1 year ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Mar 26, 2024, 7:45 AM EDT - 1 year ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 7:48 AM EDT - 1 year ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:29 AM EDT - 1 year ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 5, 2024, 4:45 PM EST - 1 year ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Feb 6, 2024, 8:01 AM EST - 1 year ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Jan 30, 2024, 8:00 AM EST - 1 year ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 4, 2024, 4:05 PM EST - 1 year ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Oct 16, 2023, 8:30 AM EDT - 2 years ago

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Sep 6, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

May 30, 2023, 8:30 AM EDT - 2 years ago

Aprea Therapeutics to Present at BIO International Convention

May 15, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

May 8, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting

Mar 1, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 27, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

Feb 22, 2023, 8:41 PM EST - 2 years ago

Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock

Bulltrader988 Oct. 25 at 8:17 PM

$APRE 👃👀 https://finviz.com/quote.ashx?t=APRE&ty=c&ta=1&p=d

0 · Reply

NewsAndFilings Oct. 25 at 2:28 PM

Weekly Rundown: $APRE Clinical Update $SNYR FOCUSfactor® Expansion $TOON $7.3 Million Financing $SIGL Major Encryption Milestone $SPTY Appoints Robert Fedder as CEO

0 · Reply

Bulltrader988 Oct. 24 at 2:36 PM

$APRE 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-provides-clinical-update-from-acesot-1051-trial-zv04tgf74l20.html

0 · Reply

MsGrumpy Oct. 24 at 2:02 PM

0 · Reply

NewsAndFilings Oct. 24 at 1:49 PM

0 · Reply

Giants67 Oct. 24 at 1:17 PM

0 · Reply

Tigerfromasia Oct. 23 at 10:11 PM

$APRE data is weak as fuck with 0 orr tbh but who gives a shit if we could get a pump

0 · Reply

Bulltrader988 Oct. 23 at 6:53 PM

$APRE tomorrow 👃👀

1 · Reply

Wakaas93 Oct. 23 at 3:52 PM

$APRE Results tomorrow Target $3 https://x.com/pportfolioooo/status/1980337875326828605?s=46

0 · Reply

Bulltrader988 Oct. 22 at 7:43 PM

0 · Reply

Carlosjr1996 Oct. 21 at 9:51 AM

$APRE squeez coming 👀??

0 · Reply

sally2884 Oct. 20 at 6:54 PM

$APRE "we may offer and sell shares of our common stock having an aggregate offering price of up to $3,000,000 Wainwright acting as our agent."

0 · Reply

NewsAndFilings Oct. 19 at 5:16 AM

Weekly Rundown: $SIGL Cybersecurity Advances $MYSE Israeli Patent & US Patent Notice $PRSO Toronto Microcap Attendance & Purchase Orders $RDZN 6 Major Ecommerce Clients & Major Auto Insurance Win $APRE Establishes Recommended Phase 2 Dose

0 · Reply

IN0V8 Oct. 17 at 3:50 PM

$APRE announced the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119 in its ongoing ABOYA-119 study for advanced solid tumors. The company is pausing further monotherapy enrollment to focus on combination therapies, leveraging ATRN-119’s potential synergistic effects with DNA-damaging agents. This strategic shift aims to enhance the therapeutic potential of ATRN-119, with ongoing discussions for combination studies in HPV+ head and neck cancer and other indications. The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. https://www.msn.com/en-us/health/other/aprea-therapeutics-shifts-focus-to-combination-therapies/ar-AA1Ox205

0 · Reply

NewsAndFilings Oct. 16 at 12:04 PM

Yesterday's Recap: $GNIS Strategic Letter of Intent With Metrospaces, Inc $APRE Establishes Recommended Phase 2 Dose $PRSO Presenting at Planet MicroCap Showcase: Toronto 2025

0 · Reply

MsGrumpy Oct. 15 at 12:58 PM

$APRE Aprea Therapeutics, Phase 2 Dosing Update: https://www.globenewswire.com/news-release/2025/10/15/3167027/0/en/Aprea-Therapeutics-Establishes-Recommended-Phase-2-Dose-RP2D-for-ATRN-119-Considering-Combination-Therapies.html

1 · Reply

NewsAndFilings Oct. 15 at 12:57 PM

$APRE Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies https://www.globenewswire.com/news-release/2025/10/15/3167027/0/en/Aprea-Therapeutics-Establishes-Recommended-Phase-2-Dose-RP2D-for-ATRN-119-Considering-Combination-Therapies.html

0 · Reply

Giants67 Oct. 15 at 12:41 PM

0 · Reply

twighttrades1 Oct. 15 at 1:11 AM

$APRE - id love to hear more concrete press woth a little more bang - but their being so slight with data presentations and and all is actually a good sign… wont take much for this to pop big

0 · Reply

thedonutman Oct. 3 at 3:48 PM

$APRE I am new here. Bought in yesterday. One question: are they expecting revenue sometime in the near future? Thank you.

1 · Reply

bgurps Oct. 3 at 3:16 PM

$APRE

0 · Reply

AlwaysLearning72 Oct. 3 at 12:36 PM

$APRE hopefully we get some positive news on their pipeline soon

0 · Reply

Market Cap	8.85M
Revenue (ttm)	1.50M
Net Income (ttm)	-12.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-864.00%
Debt to Equity Ratio	0.00

Volume	432,700
Avg Vol	74,278
Day's Range	N/A - N/A
Shares Out	5.83M
Stochastic %K	9%
Beta	1.30
Analysts	Strong Sell
Price Target	$13.67